Hemophilia care in the state of Rio de Janeiro, Brazil

In the developing countries of the world, few people with hemophilia receive adequate care. Nevertheless, Brazil has made significant advances in the treatment of hemophilia over the last decade. The provision of factor concentrates imported by the Government of Brazil is gradually increasing, and patients receive the concentrates for free. A national register was established as well as a coordinated program for comprehensive care. Of the 6 297 persons with hemophilia in Brazil who were registered as of January 2001, 689 of them (11.1 percent) were registered in the state of Rio de Janeiro. Of those 689, 664 of them were being monitored at the state's coordinating blood transfusion center, which is located in the city of Rio de Janeiro. Among those 664, factor VIII inhibitors were identified in 81 of them (12.2 percent). Among 653 of the Rio de Janeiro patients who were tested for transfusion-transmitted diseases, the overall prevalence found was 41.5 percent, with the specific rates being 13.3 percent for human immunodeficiency virus (HIV), 2.9 percent for hepatitis B virus (HBV), and 39.4 percent for hepatitis C virus (HCV). The state of Rio de Janeiro has adopted a comprehensive hemophilia management approach that includes medical, psychological, and social care. As a result, the quality of life of hemophilia patients has improved noticeably. For example, the rate of hospitalization among patients fell by 30 percent between 1998 and 2001, and there has also been a decline in the school and work activities that they have missed

Hemoglobinopatias em trabalhadores expostos à riscos ocupacionais / Hemoglobinopathies in workers exposed to occupational hazards

Hemoglobinopathies have been considered the most frequent hereditary disease in Brazilian population, constituting a Public Health problem. This paper reports on screening in workers at FIOCRUZ-RJ., exposed to some hazards factors such as, chemical substances, radiation, excessive cold and heat etc., with the objective of evaluating the impact of these factors in carriers of hemoglobinopathies, mainly in sickle cell trait (AS).